{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:00:56Z","timestamp":1780758056370,"version":"3.54.1"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"S5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Relate anemia to treatment outcome in a number of solid tumors. Relate hemoglobin level to quality of life. Describe the potential adverse consequences of overtreating anemia.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit atCME.TheOncologist.com<\/jats:p>\n                  <jats:p>Increasingly, anemia is being recognized as a negative prognostic and predictive factor for patients undergoing chemotherapy, radiation therapy, or a combination of these treatment modalities. The results of clinical studies have shown correlations between anemia and shorter survival times in patients with a wide variety of solid tumors and hematologic malignancies, including lung, ovarian, breast, and head\/neck cancers, non-Hodgkin's lymphoma, Hodgkin's disease, Waldenstr\u00f6m's macroglobulinemia, and chronic lymphocytic leukemia. Also, anemia has been shown to predict treatment response in patients with ovarian, cervical, and urothelial cancers, mantle cell lymphoma, and chronic lymphocytic leukemia, as well as refractory\/relapsed acute myelogenous leukemia. Based on the presumed causal relationship between anemia and poor patient outcome, several studies have examined the influence of epoetin alfa (a recombinant human erythropoietin) on outcomes in anemic patients undergoing cancer treatment. The results of these studies have been encouraging, with indications of greater locoregional tumor control and higher response rates in epoetin alfa-treated patients. Additionally, epoetin alfa therapy, by correcting anemia, has been shown to improve a patient's energy level, ability to perform daily activities, and overall quality of life (QOL). Such effects not only enhance a patient's general well-being, but may also increase their tolerance of, and willingness to undergo, full courses of their cancer therapy in a timely manner. These findings support the use of epoetin alfa to achieve gains in QOL and cancer treatment outcomes in anemic cancer patients and suggest that additional studies be conducted to further investigate the potential benefits of this agent in regard to improved outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-90005-55","type":"journal-article","created":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T19:18:13Z","timestamp":1102706293000},"page":"55-69","source":"Crossref","is-referenced-by-count":21,"title":["rHuEPO and Treatment Outcomes: the Clinical Experience"],"prefix":"10.1093","volume":"9","author":[{"given":"Clifford A.","family":"Hudis","sequence":"first","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Van Belle","sequence":"additional","affiliation":[{"name":"University Hospital Ghent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Chang","sequence":"additional","affiliation":[{"name":"Durham Regional Cancer Centre, Oshawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Muenstedt","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"2021122209454843200_R1","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"issue":"suppl 8","key":"2021122209454843200_R2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90213-1","article-title":"The impact of hemoglobin levels on treatment outcomes in patients with cancer","volume":"28","author":"Littlewood","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454843200_R3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1634\/theoncologist.7-6-492","article-title":"Impact of tumor hypoxia and anemia on radiation therapy outcomes","volume":"7","author":"Harrison","year":"2002","journal-title":"The Oncologist"},{"key":"2021122209454843200_R4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(03)00093-3","article-title":"Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy","volume":"47","author":"Belle","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122209454843200_R5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00066-004-1123-7","article-title":"Blood hemoglobin level and treatment outcome of early breast cancer","volume":"180","author":"Henke","year":"2004","journal-title":"Strahlenther Onkol"},{"key":"2021122209454843200_R6","first-page":"216a","article-title":"Hemoglobin concentration before chemotherapy is an independent prognostic factor in ovarian carcinomas","volume":"21","author":"Muenstedt","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R7","first-page":"65a","article-title":"Influence of anemia on local relapse-free survival (LRFS) of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: an analysis of the Austrian Breast Cancer Study Group","volume":"21","author":"Sevelda","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00066-003-1043-y","article-title":"Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure","volume":"179","author":"Morganti","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"2021122209454843200_R9","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E","article-title":"The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix","volume":"86","author":"Grogan","year":"1999","journal-title":"Cancer"},{"issue":"suppl 8","key":"2021122209454843200_R10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0093-7754(01)90215-5","article-title":"The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience","volume":"28","author":"Thomas","year":"2001","journal-title":"Semin Oncol"},{"issue":"suppl 6","key":"2021122209454843200_R11","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/S0959-8049(01)81022-4","article-title":"Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study","volume":"37","author":"Antonadou","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122209454843200_R12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(01)01488-2","article-title":"Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx","volume":"50","author":"Glaser","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454843200_R13","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R14","first-page":"206a","article-title":"Sequential adjuvant chemo-radiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer\u2014second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study","volume":"21","author":"Blohmer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R15","first-page":"500","article-title":"Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin","volume":"87","author":"Pangalis","year":"2002","journal-title":"Haematologica"},{"key":"2021122209454843200_R16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"2021122209454843200_R17","first-page":"18b","article-title":"Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life (QOL) outcomes in anemic cancer patients (pts) undergoing chemotherapy","volume":"100","author":"Littlewood","year":"2002","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122209454843200_R18","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Semin Hematol"},{"issue":"suppl 1","key":"2021122209454843200_R19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0169-5002(97)89358-0","article-title":"Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel","volume":"18","author":"Langer","year":"1997","journal-title":"Lung Cancer"},{"key":"2021122209454843200_R20","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454843200_R21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"2021122209454843200_R22","first-page":"574a","article-title":"Identifying hemoglobin level for optimal quality of life: results of an incremental analysis","volume":"18","author":"Cleeland","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R23","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R24","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122209454843200_R26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000204780","article-title":"Recombinant human erythropoietin in the treatment of the anaemia of cancer","volume":"87","author":"Abels","year":"1992","journal-title":"Acta Haematol"},{"key":"2021122209454843200_R27","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"2021122209454843200_R28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(00)90062-3","article-title":"Management of cancer-related anemia: epoetin alfa and quality of life","volume":"37","author":"Soignet","year":"2000","journal-title":"Semin Hematol"},{"key":"2021122209454843200_R29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CBC.2002.n.011","article-title":"Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy","volume":"3","author":"Demetri","year":"2002","journal-title":"Clin Breast Cancer"},{"issue":"suppl 2","key":"2021122209454843200_R30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.5-suppl_2-9","article-title":"The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2","volume":"5","author":"Curt","year":"2000","journal-title":"The Oncologist"},{"key":"2021122209454843200_R31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"The Oncologist"},{"key":"2021122209454843200_R32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"Br J Cancer"},{"issue":"suppl 2","key":"2021122209454843200_R33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0360-3016(02)03139-5","article-title":"Significant relationships between hemoglobin (Hb) levels and quality of life (QoL) during chemoradiation: findings from an incremental analysis of a 442-patient, prospective, community-based epoetin alfa study","volume":"54","author":"Shasha","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454843200_R34","first-page":"434a","article-title":"Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy","volume":"96","author":"Shasha","year":"2000","journal-title":"Blood"},{"key":"2021122209454843200_R35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0959-8049(02)00628-7","article-title":"Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa","volume":"39","author":"Patrick","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122209454843200_R36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/JCO.2003.02.136","article-title":"Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population","volume":"21","author":"Cella","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R37","first-page":"264b","article-title":"Evaluation of epoetin alfa (Procrit) 60,000 U once weekly in anemic cancer patients receiving chemotherapy","volume":"21","author":"Chap","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R38","first-page":"380a","article-title":"Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during adjuvant chemotherapy","volume":"21","author":"Hudis","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R39","first-page":"16b","article-title":"Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy","volume":"100","author":"Patton","year":"2002","journal-title":"Blood"},{"key":"2021122209454843200_R40","first-page":"501b","article-title":"Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community practice setting","volume":"100","author":"McKenzie","year":"2002","journal-title":"Blood"},{"key":"2021122209454843200_R41","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"suppl 8","key":"2021122209454843200_R42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0093-7754(01)90216-7","article-title":"Effects of epoetin alfa on the central nervous system","volume":"28","author":"Cerami","year":"2001","journal-title":"Semin Oncol"},{"issue":"suppl 5","key":"2021122209454843200_R43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.9-90005-18","article-title":"The erythropoietin receptor and its expression in tumor cells and other tissues","volume":"9","author":"Farrell","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209454843200_R44","first-page":"S138","article-title":"Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data","volume":"76","author":"O'Shaughnessy","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209454843200_R45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly. BEST Investigators and Study Group","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"2021122209454843200_R46","first-page":"543a","article-title":"Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (\u22644 +LN). First results of an AGO-trial","volume":"22","author":"M\u00f6bus","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R47","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","article-title":"Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience","volume":"9","author":"Albain","year":"1991","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R48","first-page":"126","article-title":"Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy","volume":"20","author":"Ohlhauser","year":"1997","journal-title":"Onkologie"},{"key":"2021122209454843200_R49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF03038495","article-title":"[Survival of exclusively irradiated patients with NSCLC","volume":"174","author":"Wilhelm","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"2021122209454843200_R50","first-page":"5577","article-title":"Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer","volume":"19","author":"Ylisirnio","year":"1999","journal-title":"Anticancer Res"},{"key":"2021122209454843200_R51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122209454843200_R52","first-page":"639","article-title":"Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer","volume":"7","author":"Obermair","year":"2000","journal-title":"Oncol Rep"},{"key":"2021122209454843200_R53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/1097-0142(20010815)92:4<903::AID-CNCR1399>3.0.CO;2-2","article-title":"Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results","volume":"92","author":"Obermair","year":"2001","journal-title":"Cancer"},{"key":"2021122209454843200_R54","first-page":"216a","article-title":"Pretreatment serum hemoglobin as a prognostic factor in epithelial ovarian cancer","volume":"21","author":"Marinaccio","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454843200_R55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1442-2042.1998.tb00380.x","article-title":"Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma","volume":"5","author":"Masuda","year":"1998","journal-title":"Int J Urol"},{"key":"2021122209454843200_R56","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002800000176","article-title":"Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer","volume":"46","author":"Sengelov","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122209454843200_R58","first-page":"831","article-title":"A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies","volume":"5","author":"Vollmer","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122209454843200_R59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/PL00002331","article-title":"Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery","volume":"176","author":"Wagner","year":"2000","journal-title":"Strahlenther Onkol"},{"key":"2021122209454843200_R60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1023\/A:1008498705032","article-title":"Frequency and significance of anemia in non-Hodgkin's lymphoma patients","volume":"9","author":"Moullet","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122209454843200_R61","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"2021122209454843200_R62","first-page":"993","article-title":"Retrospective analysis of mantle cell lymphoma: experience of the \u201cGruppo Italiano per lo Studio dei Linfomi\u201d (GISL)","volume":"83","author":"Callea","year":"1998","journal-title":"Haematologica"},{"key":"2021122209454843200_R63","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"2021122209454843200_R64","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122209454843200_R65","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2000.18.7.1500","article-title":"Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy\u2014results of the French Society of Pediatric Oncology Study MDH90","volume":"18","author":"Landman-Parker","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209454843200_R66","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0360-3016(98)00151-5","article-title":"Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors","volume":"41","author":"Liao","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454843200_R67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009057630","article-title":"Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia","volume":"37","author":"Keating","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"2021122209454843200_R68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.leu.2401668","article-title":"Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities","volume":"14","author":"Kern","year":"2000","journal-title":"Leukemia"},{"key":"2021122209454843200_R69","first-page":"852","article-title":"Prognostic factors in Waldenstr\u00f6m macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients","volume":"96","author":"Morel","year":"2000","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-90005-55","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-90005-55","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S5\/55\/41844436\/oncolo_9_s5_55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S5\/55\/41844436\/oncolo_9_s5_55.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:24:00Z","timestamp":1640193840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/S5\/55\/6388132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":69,"journal-issue":{"issue":"S5","published-online":{"date-parts":[[2004,11,1]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-90005-55","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,11,1]]},"published":{"date-parts":[[2004,11,1]]}}}